<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-id journal-id-type="nlm-ta">Eur J Cardiovasc Prev Rehabil</journal-id>
<journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1741826711423216</article-id>
<article-id pub-id-type="publisher-id">10.1177_1741826711423216</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Lipids</subject>
<subj-group subj-group-type="heading">
<subject>Original scientific papers</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Relationship between lipoprotein(a) concentrations and intima-media thickness: a healthy population study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Calmarza</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711423216">1</xref>
<xref ref-type="corresp" rid="corresp1-1741826711423216"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Trejo</surname><given-names>JM</given-names></name>
<xref ref-type="aff" rid="aff2-1741826711423216">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lapresta</surname><given-names>C</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711423216">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lopez</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff2-1741826711423216">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1741826711423216"><label>1</label>Hospital Universitario Miguel Servet, Zaragoza, Spain.</aff>
<aff id="aff2-1741826711423216"><label>2</label>Complejo Asistencial, Burgos, Spain.</aff>
<author-notes>
<corresp id="corresp1-1741826711423216">Pilar Calmarza, Avda. Cesáreo Alierta, no. 38 Esc 1a 5° A, Zaragoza, Spain Email: <email>mpcalmarza@salud.aragon.es</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>6</issue>
<fpage>1290</fpage>
<lpage>1295</lpage>
<history>
<date date-type="received"><day>5</day><month>2</month><year>2011</year></date>
<date date-type="accepted"><day>22</day><month>8</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<p><bold>Background:</bold> High levels of lipoprotein(a) [Lp(a)] have been linked to an increased risk of ischaemic cardiovascular events. We examined whether Lp(a) plasma levels are associated with early arteriosclerosis by measuring intima media thickness in an asymptomatic population of Burgos, Spain.</p>
<p><bold>Methods:</bold> We determined lipids, lipoprotein(a) by a nephelometry method and the intima-media thickness (IMT) in the far wall of both common carotid arteries by B-mode ultrasound in a group of 172 asymptomatic subjects.</p>
<p><bold>Results:</bold> No association was found in the population group between Lp(a) concentrations and left, right, or overall mean IMT by univariate or multivariate regression analysis. The median IMT was not significantly different in individuals with Lp(a) levels &gt;300 mg/l and in individuals with Lp(a) levels &lt;300 mg/l.</p>
<p><bold>Conclusions:</bold> These results suggest that increased Lp(a) levels do not confer cardiovascular risk by promoting early atherogenesis, but rather increasing the susceptibility to thrombosis.</p>
</abstract>
<kwd-group>
<kwd>Atherosclerotic plaques</kwd>
<kwd>cardiovascular risk</kwd>
<kwd>carotid artery</kwd>
<kwd>early arteriosclerosis</kwd>
<kwd>intima-media thickness</kwd>
<kwd>lipoprotein(a)</kwd>
<kwd>thrombosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1741826711423216" sec-type="intro"><title>Introduction</title>
<p>Atherosclerosis is a major cause of cardio- and cerebrovascular death and morbidity, but subtle structural changes, such as thickening of the arterial intima-media complex, occur early in the atherosclerotic disease, a process in which there are symptoms only when it is advanced. So the measurement of the thickness in the carotid artery is the most accepted marker of early atherosclerosis even in asymptomatic individuals<sup><xref ref-type="bibr" rid="bibr1-1741826711423216">1</xref></sup> and it has been recognized as a surrogate marker to evaluate therapeutic interventions in atherosclerotic disease.<sup><xref ref-type="bibr" rid="bibr2-1741826711423216">2</xref></sup> Because the widely accepted cardiovascular risk factors predict less than half of future cardiovascular events,<sup><xref ref-type="bibr" rid="bibr3-1741826711423216">3</xref>,<xref ref-type="bibr" rid="bibr4-1741826711423216">4</xref></sup> emerging factors such as lipoprotein(a) [Lp(a)] are being considered. This lipoprotein incorporates a low-density lipoprotein (LDL) particle and a highly polymorphic apolipoprotein(a), which is covalently linked to the apolipoprotein B moiety of the LDL by a single disulfide bridge.</p>
<p>Apolipoprotein(a) shares a striking structural resemblance to plasminogen<sup><xref ref-type="bibr" rid="bibr5-1741826711423216">5</xref></sup> and contains multiple repeated copies of a sequence that closely resembles plasminogen kringle 4, followed by two sequences homologous to kringle V and serine protease domains of plasminogen, respectively.</p>
<p>Plasma Lp(a) levels vary widely among the population, most of this variation reflecting the effects of genetic variation in LpA<sup><xref ref-type="bibr" rid="bibr6-1741826711423216">6</xref></sup> and, in Caucasian populations, there is a skewed distribution with a high prevalence of the lower levels.<sup><xref ref-type="bibr" rid="bibr7-1741826711423216">7</xref></sup></p>
<p>There are several hypothetical ways in which high levels of Lp(a) can accelerate atherosclerosis. Due to its resemblance to plasminogen, it may interfere with fibrinolysis, favouring a prothrombotic state.<sup><xref ref-type="bibr" rid="bibr8-1741826711423216">8</xref></sup> Also, atherosclerosis can be enhanced by the LDL components of Lp(a) (cholesterol and Apo B<sub>100</sub>) and high Lp(a) levels decrease tissue growth factor β activation, resulting in proliferation and migration of smooth muscle cells into the intimal layer of the arterial wall.<sup><xref ref-type="bibr" rid="bibr9-1741826711423216">9</xref></sup></p>
<p>But, despite Lp(a) being first described in 1963,<sup><xref ref-type="bibr" rid="bibr10-1741826711423216">10</xref></sup> its role today in the pathogenesis and progression of atherosclerotic lesions has still not been elucidated. Also, its association with early atherosclerosis is controversial. In this study we measured Lp(a) levels and intima media thickness in a group of asymptomatic population of Burgos, Spain.</p>
</sec>
<sec id="sec2-1741826711423216" sec-type="materials|methods"><title>Material and methods</title>
<sec id="sec3-1741826711423216"><title>Population studied</title>
<p>This study was performed on 172 asymptomatic subjects. They were randomly extracted from the records of the 200.000 referral population of Gamonal Antigua health centre of the city of Burgos, northern Spain and their age and sex percentage distribution matched that one of the Spanish population in 2004–10. The risk factor profile was determined using a questionnaire and by interview.</p>
<p>The sample size of 180 individuals was calculated to have an alpha error of 0.05 and a power of 60% to detect a 0.2 mm difference from a normal intima-media thickness (IMT) of 0.65 ± 0.15 mm and a 10% calculated loss, which was finally eight participants.</p>
<p>Demographic and cardiovascular risk factors were determined in a blood sample [total cholesterol, high-density lipoprotein (HDL) and LDL cholesterol, triglycerides, and Lp(a)] or through an interview, including physical examination [blood pressure, body mass index (BMI), hip−waist ratio]. Blood pressure was assessed by the mean of two systolic and diastolic readings after 10 minutes of rest in supine position. Hypertension was defined as a systolic/diastolic blood pressure &gt;140/95 mmHg or current use of antihypertensive drugs. Subjects with major cardiovascular events (myocardial infarction, stroke, limb amputation due to peripheral artery disease) were not included. The study was approved by the Research Committee of the referral hospital.</p>
</sec>
<sec id="sec4-1741826711423216"><title>Analytical methods</title>
<p>Venous blood samples were obtained under standardized conditions<sup><xref ref-type="bibr" rid="bibr11-1741826711423216">11</xref></sup> and after 12 or more hours of fasting. Total cholesterol and triglycerides where determined enzymatically (Roche Diagnostics), LDL cholesterol using the Friedewald formula, and very-low-density lipoprotein cholesterol by dividing the triglycerides concentration by 2.18. Lp(a) in serum was quantified by a commercially available rate nephelometry method (Siemens, Marburg, Germany) with an analytical sensitivity of 0.002 g/l, no cross-reactivity with apolipoprotein B (&lt;1%) and a &lt;5% cross-reactivity with plasminogen. Apolipoprotein(a) size heterogeneity has only a moderate effect on Lp(a) recovery.<sup><xref ref-type="bibr" rid="bibr12-1741826711423216">12</xref></sup></p>
</sec>
<sec id="sec5-1741826711423216"><title>Intima-media thickness determination</title>
<p>After informed consent, IMT was determined by B-mode ultrasound in the left and right far wall of the common carotid artery, 1 cm proximal to its bifurcation. The ultrasound equipment was a HP lmage Point with a 10 MHz linear probe that was placed on the neck of the subjects who laid supine, parallel to its longitudinal axis, in an anterolateral plane (60° angle, being 0° the horizontal). Each measurement was performed twice and the mean value recorded. The mean of the right and left IMT was then calculated. Measurements of the thickness of the carotid intima-media, were made in the far wall of both common carotid arteries, 1 cm proximal to its bifurcation, where there is less change between repeated measurements and the mean values of both carotids were calculated. Measurements were conducted blind with the rest of the data concealed, by a researcher specifically trained for this purpose. To assess inter-observer consistency, one investigator (JMT) measured a subset of the sample, following the same procedure and the intraclass coefficient was calculated using the measurements of both observers. When the discrepancies between both observers were higher than 10%, a consensus measurement was made.</p>
<p>An atheroma plaque was defined echographically as a hyperechogenicity or protrusion in the vascular lumen of the intima of at least twice the thickness of the adjacent intima-media.</p>
</sec>
<sec id="sec6-1741826711423216"><title>Statistical analysis</title>
<p>All measurements except IMT were considered independent variables and were summarized by their mean and standard deviation when they were normally distributed and by median and interquartile ranges when not (as for triglycerides, Lp(a) concentrations, and IMT). To assess the relationship of the primary variables, IMT and Lp(a), a bivariate linear regression analysis was performed. The same analysis of IMT and secondary independent variables such as age, gender, BMI, waist−hip ratio, systolic blood pressure (SBP) and diastolic blood pressure (DBP), HDL cholesterol, LDL cholesterol, plasma triglycerides, fasting glucose, Lp(a), and family and personal history of cardiovascular disease followed. To determine the effect of Lp(a) on IMT after adjusting for secondary independent variables, a multivariate linear analysis was performed.</p>
<p>To examine the presence of a threshold for Lp(a), we categorized Lp(a) levels into quartiles. If a threshold existed, higher IMT values were expected to be found in individuals with Lp(a) levels above a certain quartile. Based on studies that attribute an Lp(a) higher than 300 mg/l to more cardiovascular risk,<sup><xref ref-type="bibr" rid="bibr13-1741826711423216">13</xref>,<xref ref-type="bibr" rid="bibr14-1741826711423216">14</xref></sup> IMT values below and above these values were compared.</p>
<p>On the other hand, the combination of high Lp(a) plasma concentration and LDL cholesterol levels increase the risk and advance of CAD<sup><xref ref-type="bibr" rid="bibr15-1741826711423216">15</xref></sup> and Lp(a) could enhance the atherogenic effect of LDL on coronary atherosclerosis and myocardial infarction.<sup><xref ref-type="bibr" rid="bibr16-1741826711423216">16</xref>,<xref ref-type="bibr" rid="bibr17-1741826711423216">17</xref></sup> Therefore, to examine whether Lp(a) had an atherogenic effect when high LDL levels are present, we repeated the analysis in individuals with LDL levels in the highest quartile.</p>
<p>The statistics program SPSS 15.0 was used for the analysis and <italic>p</italic>-values &lt;0.05 were considered to indicate statistical significance.</p>
</sec>
</sec>
<sec id="sec7-1741826711423216" sec-type="results"><title>Results</title>
<p>Anthropometric and lipoprotein parameters are shown in <xref ref-type="table" rid="table1-1741826711423216">Table 1</xref>. Lp(a) ranged from 0.04 to 3.78 µmol/l (median 0.54) with a distribution skewed to lower values both in men and women. Age ranged from 44 to 93 years (mean 64.2 years) and compound mean IMT from 0.530 mm to 1.27 mm (median 0.74 mm, interquartile range 0.22); 41 individuals (25%) had one or more plaques.
<table-wrap id="table1-1741826711423216" position="float"><label>Table 1.</label><caption><p>Anthropometric and lipoprotein parameters</p></caption>
<graphic alternate-form-of="table1-1741826711423216" xlink:href="10.1177_1741826711423216-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Variables</th>
<th><italic>n</italic></th>
<th>Descriptive statistics</th></tr></thead>
<tbody align="left">
<tr>
<td>Age (years)</td>
<td>171</td>
<td>64.20 ± 12.04</td></tr>
<tr>
<td>Weight (kg)</td>
<td>171</td>
<td>72.11 ± 11.80</td></tr>
<tr>
<td>Body mass index</td>
<td>170</td>
<td>28.13 ± 3.69</td></tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>170</td>
<td>140.67 ± 17.6</td></tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>169</td>
<td>80.43 ± 10.48</td></tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>171</td>
<td>5.53 ± 1.06</td></tr>
<tr>
<td>HDL cholesterol (mmol/l)</td>
<td>171</td>
<td>1.51 ± 0.4</td></tr>
<tr>
<td>LDL cholesterol (mmol/l)</td>
<td>171</td>
<td>3.43 ± 0.89</td></tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>168</td>
<td>10.84 (6.66)</td></tr>
<tr>
<td>Lp(a) (µmol/l)</td>
<td>168</td>
<td>0.54 (1.1)</td></tr>
<tr>
<td>Right mean IMT (mm)</td>
<td>169</td>
<td>0.73 (0.23)</td></tr>
<tr>
<td>Left mean IMT (mm)</td>
<td>169</td>
<td>0.76 (0.22)</td></tr>
<tr>
<td>Overall mean IMT (mm)</td>
<td>169</td>
<td>0.74 (0.22)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1741826711423216"><p>Values are expressed as mean ± standard deviation or median (interquartile range). BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; IMT, intima-media thickness; Lp(a), lipoprotein(a).</p></fn></table-wrap-foot>
</table-wrap></p>
<p>In the univariate regression analysis, older age, male gender, BMI, higher waist−hip ratio, and SBP were associated with thicker IMT (<xref ref-type="table" rid="table2-1741826711423216">Table 2</xref>). In multivariate linear regression analysis controlling for confounding factors, only older age, male sex, and personal history of cardiovascular disease (CVD) were significantly associated with increased left, right, or overall mean IMT (<xref ref-type="table" rid="table3-1741826711423216">Table 3</xref>). No relationship was found between IMT and Lp(a) levels in the univariate or multivariate analysis.
<table-wrap id="table2-1741826711423216" position="float"><label>Table 2.</label><caption><p>Risk factors affecting carotid atherosclerosis: univariate linear regression analysis</p></caption>
<graphic alternate-form-of="table2-1741826711423216" xlink:href="10.1177_1741826711423216-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Variables</th>
<th><italic>n</italic></th>
<th>Right mean IMT</th>
<th>Left mean IMT</th>
<th>Overall mean IMT</th></tr></thead>
<tbody align="left">
<tr>
<td>Age (years)</td>
<td>169</td>
<td>0.008 (0.006 to 0.010)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711423216">a</xref></sup></td>
<td>0.008 (0.006 to 0.009)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711423216">a</xref></sup></td>
<td>0.008 (0.006 to 0.009)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711423216">a</xref></sup></td></tr>
<tr>
<td>Sex (male vs. female)</td>
<td>169</td>
<td>0.055 (0.006 to 0.105)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711423216">a</xref></sup></td>
<td>0.067 (0.022 to 0.113)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711423216">a</xref></sup></td>
<td>0.062 (0.016 to 0.107)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711423216">a</xref></sup></td></tr>
<tr>
<td>Body mass (kg/m<sup>2</sup>)</td>
<td>168</td>
<td>0.012 (0.006 to 0.019)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711423216">a</xref></sup></td>
<td>0.012 (0.006 to 0.018)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711423216">a</xref></sup></td>
<td>0.012 (0.006 to 0.018)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711423216">a</xref></sup></td></tr>
<tr>
<td>Waist−hip ratio</td>
<td>129</td>
<td>0.359 (0.195 to 0.522)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711423216">a</xref></sup></td>
<td>0.342 (0.194 to 0.489)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711423216">a</xref></sup></td>
<td>0.350 (0.202 to 0.497)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711423216">a</xref></sup></td></tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>168</td>
<td>0.003 (0.001 to 0.004)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711423216">a</xref></sup></td>
<td>0.003 (0.001 to 0.004)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711423216">a</xref></sup></td>
<td>0.003 (0.002 to 0.004)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711423216">a</xref></sup></td></tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>167</td>
<td>−0.001 (−0.003 to 0.002)</td>
<td>−0.002 (−0.004 to 0.001)</td>
<td>−0.001 (−0.003 to 0.001)</td></tr>
<tr>
<td>Personal history CVD (yes vs. no)</td>
<td>168</td>
<td>−0.041 (−0.122 to 0.041)</td>
<td>−0.038 (−0.114 to 0.037)</td>
<td>−0.039 (−0.113 to 0.036)</td></tr>
<tr>
<td>Family history CVD (yes vs. no)</td>
<td>168</td>
<td>0.027 (−0.024 to 0.078)</td>
<td>0.013 (−0.034 to 0.061)</td>
<td>0.021 (−0.026 to 0.068)</td></tr>
<tr>
<td>Fasting glucose (mmol/l)</td>
<td>169</td>
<td>−0.005 (−0.030 to 0.021)</td>
<td>−0.001 (−0.025 to 0.023)</td>
<td>−0.003 (−0.026 to 0.021)</td></tr>
<tr>
<td>Total triglycerides (mmol/l)</td>
<td>169</td>
<td>0.006 (−0.021 to 0.032)</td>
<td>0.002 (−0.023 to 0.026)</td>
<td>0.004 (−0.020 to 0.028)</td></tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>169)</td>
<td>0.002 (−0.022 to 0.027)</td>
<td>−0.012 (−0.035 to 0.011)</td>
<td>−0.003 (−0.023 to 0.019)</td></tr>
<tr>
<td>HDL cholesterol (mmol/l)</td>
<td>169</td>
<td>−0.041 (−0.103 to 0.021)</td>
<td>−0.055 (−0.113 to 0.002)</td>
<td>−0.048 (−0.104 to 0.009)</td></tr>
<tr>
<td>LDL cholesterol (mmol/l)</td>
<td>169</td>
<td>0.010 (−0.019 to 0.040)</td>
<td>−0.004 (−0.031 to 0.023)</td>
<td>0.004 (−0.022 to 0.031)</td></tr>
<tr>
<td>Lipoprotein(a) (µmol/l)</td>
<td>162</td>
<td>−0.016 (0.045 to 0.013)</td>
<td>−0.012 (0.039 to 0.015)</td>
<td>−0.013 (0.040 to 0.013</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1741826711423216"><p>Values are regression coefficient or carotid artery IMT change in mm (95% confidence interval). BP, blood pressure; CVD, cardiovascular disease; HDL, high-density lipoprotein; IMT, intima-media thickness; LDL, low-density lipoprotein. <sup>a</sup><italic>p</italic>-value &lt;0.05.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table3-1741826711423216" position="float"><label>Table 3.</label><caption><p>Risk factors affecting carotid atherosclerosis: multivariate linear regression analysis</p></caption>
<graphic alternate-form-of="table3-1741826711423216" xlink:href="10.1177_1741826711423216-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Variables in the best explanation model</th>
<th>Right mean IMT (<italic>n</italic> = 168, <italic>R</italic><sup>2 </sup>= 0.414)</th>
<th>Left mean IMT (<italic>n</italic> = 169, <italic>R</italic><sup>2 </sup>= 0.0.451)</th>
<th>Overall mean IMT (<italic>n</italic> = 167, <italic>R</italic><sup>2 </sup>= 0.461)</th></tr></thead>
<tbody align="left">
<tr>
<td>Age (years)</td>
<td>0.009 (0.007 to 0.011)<sup>a</sup></td>
<td>0.008 (0.007 to 0.010)<sup>a</sup></td>
<td>0.008 (0.006−0.010)<sup>a</sup></td></tr>
<tr>
<td>Sex (male vs. female)</td>
<td>0.080 (0.040 to 0.120)<sup>a</sup></td>
<td>0.068 (0.02870.109)<sup>a</sup></td>
<td>0.078 (0.043−0.114)<sup>a</sup></td></tr>
<tr>
<td>Body mass index (kg/m<sup>2</sup>)</td>
<td/>
<td>0.004 (−0.001 to 0.009)</td>
<td/></tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td/>
<td/>
<td>0.001 (0.000−0.002)<sup>a</sup></td></tr>
<tr>
<td>Personal history CVD</td>
<td>0.061 (−0.005 to 0.128)</td>
<td>0.072 (0.012 to 0.133)<sup>a</sup></td>
<td>0.066 (0.007−0.125)<sup>a</sup></td></tr>
<tr>
<td>LDL cholesterol (mmol/l)</td>
<td>0.020 (−0,003 to 0.043)</td>
<td/>
<td/></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1741826711423216"><p>Values are regression coefficient or carotid artery IMT change in mm (95% confidence interval). BP, blood pressure; CVD, cardiovascular disease; HDL, high-density lipoprotein; IMT, intima-media thickness; LDL, low-density lipoprotein; <italic>R</italic><sup>2</sup>, coefficient of determination. <sup>a</sup><italic>p</italic>-value &lt;0.05.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>When we categorized Lp(a) levels into quartiles, we did not find thicker intima-media in the higher quartiles of Lp(a) values or when dichotomizing Lp(a) into higher or lower than 300 mg/l groups, which show no difference in the number of plaques (or its thickness when present). Lp(a) in individuals with LDL cholesterol levels in the highest quartile was not associated with a thicker IMT compared with people with LDL cholesterol in the lowest quartile.</p>
</sec>
<sec id="sec8-1741826711423216" sec-type="discussion"><title>Discussion</title>
<p>There is a clear association between carotid IMT and cardiovascular risk factors,<sup><xref ref-type="bibr" rid="bibr18-1741826711423216">18</xref>,<xref ref-type="bibr" rid="bibr19-1741826711423216">19</xref></sup> thus the association of older age, male gender, BMI, waist−hip ratio, SBP, and cardiovascular familiar antecedents (<xref ref-type="table" rid="table2-1741826711423216">Table 2</xref>) is not unexpected. On the contrary, the relationship between Lp(a) and early atherosclerosis of carotid arteries is controversial. Among studies in special subgroups of population, no relationship was found in patients with bone fractures,<sup><xref ref-type="bibr" rid="bibr20-1741826711423216">20</xref></sup> elderly patients,<sup><xref ref-type="bibr" rid="bibr21-1741826711423216">21</xref></sup> young healthy volunteers,<sup><xref ref-type="bibr" rid="bibr22-1741826711423216">22</xref></sup> or high cardiovascular risk patients.<sup><xref ref-type="bibr" rid="bibr23-1741826711423216">23</xref></sup> But special populations, and in particular hospital-based samples, cannot be extrapolated to the general population, as they are subject to referral bias, high risk factor profile, and old age overrepresentation.</p>
<p>Population-based studies on this subject are scarce and have been done in German<sup><xref ref-type="bibr" rid="bibr24-1741826711423216">24</xref></sup> and African American populations,<sup><xref ref-type="bibr" rid="bibr25-1741826711423216">25</xref></sup> in which some influence of Lp(a) levels in IMT has been found. Considering the importance of genetic background in Lp(a) levels, we attempted a population study in a southern Europe (Mediterranean) country, randomly selecting the subjects, stratified in order to be representative of the Spanish population. We did not find any relationship between Lp(a) levels and IMT in univariate or multivariate analysis. There was also an absence of relationship when analysing the subgroup of high LDL cholesterol levels, suggesting that Lp(a) does not potentiate early atherosclerosis by interacting with LDL cholesterol. Also, a threshold level for Lp(a) having early atherogenic properties is not suggested by our findings. In contrast, the large population-based Atherosclerotic Risk in Communities (ARIC) cohort suggested a weak but significant correlation between Lp(a) concentration and IMT values in a study population from different ethnic groups.</p>
<p>How can our data be put in perspective of this large studies? The small size of our sample is the principal limitation of our study and could be responsible for our not detecting the already small effect of Lp(a) on IMT found in ARIC. ARIC's non-homogeneous ethnic background, clearly different from our study, is a more likely explanation. Indeed, the association of carotid IMT with Lp(a) varies in different groups and it is not associated in some.<sup><xref ref-type="bibr" rid="bibr26-1741826711423216">26</xref></sup> Also, a collaborative analysis of individual data from 36 prospective studies, involving more than 126,000 subjects, has shown a linear association between Lp(a) and coronary and cerebrovascular disease, independently from other conventional risk factors.<sup><xref ref-type="bibr" rid="bibr27-1741826711423216">27</xref></sup> This association with clinical events suggests that Lp(a) has a more important role in fully developed<sup><xref ref-type="bibr" rid="bibr28-1741826711423216">28</xref>,<xref ref-type="bibr" rid="bibr29-1741826711423216">29</xref></sup> than early atherosclerosis. Apolipoprotein(a) can induce vascular endothelial cell growth, migration, contraction, and cell permeability<sup><xref ref-type="bibr" rid="bibr30-1741826711423216">30</xref>,<xref ref-type="bibr" rid="bibr31-1741826711423216">31</xref></sup> and the ability to preferentially bind proinflamatory oxidized phospholipids.<sup>32</sup> Alternatively, due to the structural similarities of plasminogen and Lp(a), this could interfere with fibrinolysis, favouring a prothrombotic state<sup><xref ref-type="bibr" rid="bibr8-1741826711423216">8</xref></sup> and provoking the clinical event through plaque thrombosis.</p>
<p>In conclusion, in a sample of the general Spanish population, we did not find a relationship between Lp(a) levels and the early atherosclerosis marker carotid artery IMT.</p>
</sec>
</body>
<back>
<sec id="sec9-1741826711423216"><title>Funding</title>
<p>This research was partially supported by a grant from Castilla y León regional government.</p>
</sec>
<sec id="sec10-1741826711423216"><title>Conflict of interests</title>
<p>The authors declare that there is no conflict of interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-1741826711423216"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Touboul</surname><given-names>PJ</given-names></name><name><surname>Labreuche</surname><given-names>J</given-names></name><name><surname>Vicaut</surname><given-names>E</given-names></name><name><surname>Amarenco</surname><given-names>P</given-names></name></person-group>. <article-title>Carotid intima-media thickness, plaques, and Framingham risk score as independent determinants of stroke risk</article-title>. <source>Stroke</source> <year>2005</year>; <volume>36</volume>(<issue>8</issue>): <fpage>1741</fpage>–<lpage>1745</lpage>.</citation></ref>
<ref id="bibr2-1741826711423216"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Masoura</surname><given-names>C</given-names></name><name><surname>Pitsavos</surname><given-names>C</given-names></name><name><surname>Aznaouridis</surname><given-names>K</given-names></name><name><surname>Skoumas</surname><given-names>I</given-names></name><name><surname>Vlachopoulos</surname><given-names>C</given-names></name><name><surname>Stefanadis</surname><given-names>C</given-names></name></person-group>. <article-title>Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis</article-title>. <source>Atherosclerosis</source> <year>2011</year>; <volume>214</volume>(<issue>1</issue>): <fpage>129</fpage>–<lpage>138</lpage>.</citation></ref>
<ref id="bibr3-1741826711423216"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van den Berg</surname><given-names>E</given-names></name><name><surname>Biessels</surname><given-names>GJ</given-names></name><name><surname>Stehouwer</surname><given-names>CD</given-names></name><name><surname>Kappelle</surname><given-names>LJ</given-names></name><name><surname>Heine</surname><given-names>RJ</given-names></name><name><surname>Nijpels</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Ten-year time course of risk factors for increased carotid intima-media thickness: the Hoorn Study</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2010</year>; <volume>17</volume>(<issue>2</issue>): <fpage>168</fpage>–<lpage>174</lpage>.</citation></ref>
<ref id="bibr4-1741826711423216"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rasouli</surname><given-names>ML</given-names></name><name><surname>Nasir</surname><given-names>K</given-names></name><name><surname>Blumenthal</surname><given-names>RS</given-names></name><name><surname>Park</surname><given-names>R</given-names></name><name><surname>Aziz</surname><given-names>DC</given-names></name><name><surname>Budoff</surname><given-names>MJ</given-names></name></person-group>. <article-title>Plasma homocysteine predicts progression of atherosclerosis</article-title>. <source>Atherosclerosis</source> <year>2005</year>; <volume>181</volume>(<issue>1</issue>): <fpage>159</fpage>–<lpage>165</lpage>.</citation></ref>
<ref id="bibr5-1741826711423216"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McLean</surname><given-names>JW</given-names></name><name><surname>Tomlinson</surname><given-names>JE</given-names></name><name><surname>Kuang</surname><given-names>WJ</given-names></name><name><surname>Eaton</surname><given-names>DL</given-names></name><name><surname>Chen</surname><given-names>EY</given-names></name><name><surname>Fless</surname><given-names>GM</given-names></name><etal/></person-group>. <article-title>cDNA sequence of human apolipoprotein(a) is homologous to plasminogen</article-title>. <source>Nature</source> <year>1987</year>; <volume>330</volume>(<issue>6144</issue>): <fpage>132</fpage>–<lpage>137</lpage>.</citation></ref>
<ref id="bibr6-1741826711423216"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berglund</surname><given-names>L</given-names></name><name><surname>Ramakrishnan</surname><given-names>R</given-names></name></person-group>. <article-title>Lipoprotein(a): an elusive cardiovascular risk factor</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2004</year>; <volume>24</volume>(<issue>12</issue>): <fpage>2219</fpage>–<lpage>2226</lpage>.</citation></ref>
<ref id="bibr7-1741826711423216"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marcovina</surname><given-names>SM</given-names></name><name><surname>Albers</surname><given-names>JJ</given-names></name><name><surname>Jacobs</surname><given-names>DR</given-names><suffix>Jr</suffix></name><name><surname>Perkins</surname><given-names>LL</given-names></name><name><surname>Lewis</surname><given-names>CE</given-names></name><name><surname>Howard</surname><given-names>BV</given-names></name><etal/></person-group>. <article-title>Lipoprotein[a] concentrations and apolipoprotein[a] phenotypes in Caucasians and African Americans. The CARDIA study</article-title>. <source>Arterioscler Thromb</source> <year>1993</year>; <volume>13</volume>(<issue>7</issue>): <fpage>1037</fpage>–<lpage>1045</lpage>.</citation></ref>
<ref id="bibr8-1741826711423216"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miles</surname><given-names>LA</given-names></name><name><surname>Fless</surname><given-names>GM</given-names></name><name><surname>Scanu</surname><given-names>AM</given-names></name><name><surname>Baynham</surname><given-names>P</given-names></name><name><surname>Sebald</surname><given-names>MT</given-names></name><name><surname>Skocir</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Interaction of Lp(a) with plasminogen binding sites on cells</article-title>. <source>Thromb Haemost</source> <year>1995</year>; <volume>73</volume>(<issue>3</issue>): <fpage>458</fpage>–<lpage>465</lpage>.</citation></ref>
<ref id="bibr9-1741826711423216"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kirschenlohr</surname><given-names>HL</given-names></name><name><surname>Metcalfe</surname><given-names>JC</given-names></name><name><surname>Weissberg</surname><given-names>PL</given-names></name><name><surname>Grainger</surname><given-names>DJ</given-names></name></person-group>. <article-title>Proliferation of human aortic vascular smooth muscle cells in culture is modulated by active TGF beta</article-title>. <source>Cardiovasc Res</source> <year>1995</year>; <volume>29</volume>(<issue>6</issue>): <fpage>848</fpage>–<lpage>855</lpage>.</citation></ref>
<ref id="bibr10-1741826711423216"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>K</given-names></name></person-group>. <article-title>A new serum type system in man- the Lp system</article-title>. <source>Acta Pathol Microbiol Scand</source> <year>1963</year>; <volume>59</volume>: <fpage>369</fpage>–<lpage>382</lpage>.</citation></ref>
<ref id="bibr11-1741826711423216"><label>11</label><citation citation-type="journal"><collab>Sociedad Española de Bioquímica Clínica y Patología Molecular</collab>. <article-title>Comisión de Lípidos y Lipoproteínas. Protocolo para la obtención de especimenes en las determinaciones de lípidos y lipoproteínas</article-title>. <source>Quím Clin</source> <year>1989</year>; <volume>8</volume>(<issue>5</issue>): <fpage>349</fpage>–<lpage>361</lpage>.</citation></ref>
<ref id="bibr12-1741826711423216"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marcovina</surname><given-names>SM</given-names></name><name><surname>Albers</surname><given-names>JJ</given-names></name><name><surname>Scanu</surname><given-names>AM</given-names></name><name><surname>Kennedy</surname><given-names>H</given-names></name><name><surname>Giaculli</surname><given-names>F</given-names></name><name><surname>Couderc</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Use of a reference material proposed by The International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)</article-title>. <source>Clin Chem</source> <year>2000</year>; <volume>46</volume>(<issue>12</issue>): <fpage>1956</fpage>–<lpage>1967</lpage>.</citation></ref>
<ref id="bibr13-1741826711423216"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dahlen</surname><given-names>GH</given-names></name><name><surname>Guyton</surname><given-names>JR</given-names></name><name><surname>Attar</surname><given-names>M</given-names></name><name><surname>Farmer</surname><given-names>JA</given-names></name><name><surname>Kautz</surname><given-names>JA</given-names></name><name><surname>Gotto</surname><given-names>AM</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography</article-title>. <source>Circulation</source> <year>1986</year>; <volume>74</volume>(<issue>4</issue>): <fpage>758</fpage>–<lpage>765</lpage>.</citation></ref>
<ref id="bibr14-1741826711423216"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosengren</surname><given-names>A</given-names></name><name><surname>Wilhelmsen</surname><given-names>L</given-names></name><name><surname>Eriksson</surname><given-names>E</given-names></name><name><surname>Risberg</surname><given-names>B</given-names></name><name><surname>Wedel</surname><given-names>H</given-names></name></person-group>. <article-title>Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men</article-title>. <source>BMJ</source> <year>1990</year>; <volume>301</volume>(<issue>6763</issue>): <fpage>1248</fpage>–<lpage>1251</lpage>.</citation></ref>
<ref id="bibr15-1741826711423216"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>VW</given-names></name><name><surname>Cremer</surname><given-names>P</given-names></name><name><surname>Eberle</surname><given-names>E</given-names></name><name><surname>Manke</surname><given-names>A</given-names></name><name><surname>Schulze</surname><given-names>F</given-names></name><name><surname>Wieland</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis</article-title>. <source><italic>Dependence on serum LDL levels</italic>. Atherosclerosis</source> <year>1986</year>; <volume>62</volume>(<issue>3</issue>): <fpage>249</fpage>–<lpage>257</lpage>.</citation></ref>
<ref id="bibr16-1741826711423216"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kitajima</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Koike</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Shiomi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Lp(a) enhances coronary atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits</article-title>. <source>Atherosclerosis</source> <year>2007</year>; <volume>193</volume>(<issue>2</issue>): <fpage>269</fpage>–<lpage>276</lpage>.</citation></ref>
<ref id="bibr17-1741826711423216"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baldassarre</surname><given-names>D</given-names></name><name><surname>Tremoli</surname><given-names>E</given-names></name><name><surname>Franceschini</surname><given-names>G</given-names></name><name><surname>Michelagnoli</surname><given-names>S</given-names></name><name><surname>Sirtori</surname><given-names>CR</given-names></name></person-group>. <article-title>Plasma lipoprotein (a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients</article-title>. <source>Stroke</source> <year>1996</year>; <volume>27</volume>(<issue>6</issue>): <fpage>1044</fpage>–<lpage>1049</lpage>.</citation></ref>
<ref id="bibr18-1741826711423216"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fadini</surname><given-names>GP</given-names></name><name><surname>Coracina</surname><given-names>A</given-names></name><name><surname>Inchiostro</surname><given-names>S</given-names></name><name><surname>Tiengo</surname><given-names>A</given-names></name><name><surname>Avogaro</surname><given-names>A</given-names></name><name><surname>de Kreutzenberg</surname><given-names>SV</given-names></name></person-group>. <article-title>A stepwise approach to assess the impact of clustering cardiometabolic risk factors on carotid intima-media thickness: the metabolic syndrome no-more-than-additive</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2008</year>; <volume>15</volume>(<issue>2</issue>): <fpage>190</fpage>–<lpage>196</lpage>.</citation></ref>
<ref id="bibr19-1741826711423216"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Michele</surname><given-names>M</given-names></name><name><surname>Iannuzzi</surname><given-names>A</given-names></name><name><surname>Panico</surname><given-names>S</given-names></name><name><surname>Celentano</surname><given-names>E</given-names></name><name><surname>Sacchetti</surname><given-names>L</given-names></name><name><surname>Mazzaccara</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Effect of high-density lipoprotein cholesterol levels on carotid artery geometry in a Mediterranean female population</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2004</year>; <volume>11</volume>(<issue>5</issue>): <fpage>403</fpage>–<lpage>407</lpage>.</citation></ref>
<ref id="bibr20-1741826711423216"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Srámek</surname><given-names>A</given-names></name><name><surname>Reiber</surname><given-names>JH</given-names></name><name><surname>Baak-Pablo</surname><given-names>R</given-names></name><name><surname>Sturk</surname><given-names>A</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name></person-group>. <article-title>Lipoprotein(a) and ultrasonographically determined early atherosclerotic changes in the carotid and femoral artery</article-title>. <source>J Thromb Haemost</source> <year>2003</year>; <volume>1</volume>(<issue>2</issue>): <fpage>374</fpage>–<lpage>379</lpage>.</citation></ref>
<ref id="bibr21-1741826711423216"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denti</surname><given-names>L</given-names></name><name><surname>Marchini</surname><given-names>L</given-names></name><name><surname>Pasolini</surname><given-names>G</given-names></name><name><surname>Baffoni</surname><given-names>MT</given-names></name><name><surname>Ablondi</surname><given-names>F</given-names></name><name><surname>Valenti</surname><given-names>G</given-names></name></person-group>. <article-title>Lipoprotein Lp(a) and cerebrovascular disease in the elderly: correlations with the severity of extracranial carotid atherosclerosis assessed by ultrasonography</article-title>. <source>Acta Biomed Ateneo Parmense</source> <year>1995</year>; <volume>66</volume>(<issue>3–4</issue>): <fpage>175</fpage>–<lpage>183</lpage>.</citation></ref>
<ref id="bibr22-1741826711423216"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grebe</surname><given-names>MT</given-names></name><name><surname>Schoene</surname><given-names>E</given-names></name><name><surname>Schaefer</surname><given-names>CA</given-names></name><name><surname>Boedeker</surname><given-names>RH</given-names></name><name><surname>Kemkes-Matthes</surname><given-names>B</given-names></name><name><surname>Voss</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Elevated Lipoprotein (a) does not promote early atherosclerotic changes of the carotid arteries in young, healthy adults</article-title>. <source>Atherosclerosis</source> <year>2007</year>; <volume>190</volume>(<issue>1</issue>): <fpage>194</fpage>–<lpage>198</lpage>.</citation></ref>
<ref id="bibr23-1741826711423216"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El-Gendi</surname><given-names>SS</given-names></name><name><surname>Bakeet</surname><given-names>MY</given-names></name><name><surname>El-Hamed</surname><given-names>EA</given-names></name><name><surname>Ibrahim</surname><given-names>FK</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name></person-group>. <article-title>The value of lipoprotein (a), homocysteine, and Doppler of carotid and femoral arteries in assessment of atherosclerosis in asymptomatic cardiovascular risk patients</article-title>. <source>J Cardiol</source> <year>2008</year>; <volume>52</volume>(<issue>3</issue>): <fpage>202</fpage>–<lpage>211</lpage>.</citation></ref>
<ref id="bibr24-1741826711423216"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linnebank</surname><given-names>M</given-names></name><name><surname>Moskau</surname><given-names>S</given-names></name><name><surname>Farmand</surname><given-names>S</given-names></name><name><surname>Fliessbach</surname><given-names>K</given-names></name><name><surname>Kölsch</surname><given-names>H</given-names></name><name><surname>Bös</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Homocysteine and carotid intima-media thickness in a german population: lack of clinical relevance</article-title>. <source>Stroke</source> <year>2006</year>; <volume>37</volume>(<issue>11</issue>): <fpage>2840</fpage>–<lpage>2842</lpage>.</citation></ref>
<ref id="bibr25-1741826711423216"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>DW</given-names></name><name><surname>Chambless</surname><given-names>LE</given-names></name><name><surname>Folsom</surname><given-names>AR</given-names></name><name><surname>Heiss</surname><given-names>G</given-names></name><name><surname>Hutchinson</surname><given-names>RG</given-names></name><name><surname>Sharrett</surname><given-names>AR</given-names></name><etal/></person-group>. <article-title>Risk factors for coronary heart disease in African Americans: the atherosclerosis risk in communities study, 1987–1997</article-title>. <source>Arch Intern Med</source> <year>2002</year>; <volume>162</volume>(<issue>22</issue>): <fpage>2565</fpage>–<lpage>2571</lpage>.</citation></ref>
<ref id="bibr26-1741826711423216"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schreiner</surname><given-names>PJ</given-names></name><name><surname>Heiss</surname><given-names>G</given-names></name><name><surname>Tyroler</surname><given-names>HA</given-names></name><name><surname>Morrisett</surname><given-names>JD</given-names></name><name><surname>Davis</surname><given-names>CE</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name></person-group>. <article-title>Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>1996</year>; <volume>16</volume>(<issue>3</issue>): <fpage>471</fpage>–<lpage>478</lpage>.</citation></ref>
<ref id="bibr27-1741826711423216"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Emerging risk factors collaboration, Erqou</surname><given-names>S</given-names></name><name><surname>Kaptoge</surname><given-names>S</given-names></name><name><surname>Perry</surname><given-names>PL</given-names></name><name><surname>Di Angelantonio</surname><given-names>E</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name><name><surname>White</surname><given-names>IR</given-names></name><etal/></person-group>. <article-title>Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality</article-title>. <source>JAMA</source> <year>2009</year>; <volume>302</volume>(<issue>4</issue>): <fpage>412</fpage>–<lpage>423</lpage>.</citation></ref>
<ref id="bibr28-1741826711423216"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calmarza</surname><given-names>P</given-names></name><name><surname>Cordero</surname><given-names>J</given-names></name><name><surname>Santos</surname><given-names>V</given-names></name><name><surname>Vella</surname><given-names>JC</given-names></name></person-group>. <article-title>Apolipoprotein(a) isoforms in infarcted men under 60 years old</article-title>. <source>Clin Biochem</source> <year>2004</year>; <volume>37</volume>(<issue>10</issue>): <fpage>911</fpage>–<lpage>918</lpage>.</citation></ref>
<ref id="bibr29-1741826711423216"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamstrup</surname><given-names>PR</given-names></name><name><surname>Tybjaerg-Hansen</surname><given-names>A</given-names></name><name><surname>Steffensen</surname><given-names>R</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name></person-group>. <article-title>Genetically elevated lipoprotein(a) and increased risk of myocardial infarction</article-title>. <source>JAMA</source> <year>2009</year>; <volume>301</volume>(<issue>22</issue>): <fpage>2331</fpage>–<lpage>2339</lpage>.</citation></ref>
<ref id="bibr30-1741826711423216"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Craig</surname><given-names>AW</given-names></name><name><surname>Meldrum</surname><given-names>HD</given-names></name><name><surname>Marcovina</surname><given-names>SM</given-names></name><name><surname>Elliott</surname><given-names>BE</given-names></name><name><surname>Koschinsky</surname><given-names>ML</given-names></name></person-group>. <article-title>Apolipoprotein(a) stimulates vascular endothelial cell growth and migration and signals through integrin alphaVbeta3</article-title>. <source>Biochem J</source> <year>2009</year>; <volume>418</volume>(<issue>2</issue>): <fpage>325</fpage>–<lpage>336</lpage>.</citation></ref>
<ref id="bibr31-1741826711423216"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>T</given-names></name><name><surname>Jung</surname><given-names>Y</given-names></name><name><surname>Koschinsky</surname><given-names>ML</given-names></name></person-group>. <article-title>Apolipoprotein(a), through its strong lysine-binding site in KIV<sub>10</sub>, mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway</article-title>. <source>J Biol Chem</source> <year>2008</year>; <volume>283</volume>(<issue>45</issue>): <fpage>30503</fpage>–<lpage>30512</lpage>.</citation></ref>
<ref id="bibr32-1741826711423216"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fraley</surname><given-names>AE</given-names></name><name><surname>Schwartz</surname><given-names>GG</given-names></name><name><surname>Olsson</surname><given-names>AG</given-names></name><name><surname>Kinlay</surname><given-names>S</given-names></name><name><surname>Szarek</surname><given-names>M</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>MIRACL Study Investigators. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial</article-title>. <source>J Am Coll Cardiol</source> <year>2009</year>; <volume>53</volume>(<issue>23</issue>): <fpage>2186</fpage>–<lpage>2196</lpage>.</citation></ref>
</ref-list>
</back>
</article>